(R)-1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonyl]-piperidine-2-carboxylic acid hydroxyamide

ID: ALA341309

PubChem CID: 44351302

Max Phase: Preclinical

Molecular Formula: C17H22ClN3O4S

Molecular Weight: 399.90

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NO)[C@H]1CCCCN1S(=O)(=O)N1CC=C(c2ccc(Cl)cc2)CC1

Standard InChI:  InChI=1S/C17H22ClN3O4S/c18-15-6-4-13(5-7-15)14-8-11-20(12-9-14)26(24,25)21-10-2-1-3-16(21)17(22)19-23/h4-8,16,23H,1-3,9-12H2,(H,19,22)/t16-/m1/s1

Standard InChI Key:  HMOKTUUFXQHREN-MRXNPFEDSA-N

Molfile:  

     RDKit          2D

 26 28  0  0  1  0  0  0  0  0999 V2000
    3.2792   -1.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.0667   -1.8000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6500   -2.5125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1042   -1.0042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8250   -2.5042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7542   -1.0792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3667   -0.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5667   -0.2792    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6917   -0.4125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5500   -0.3042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5792   -1.1125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4875   -1.7292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4167   -1.7917    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3125   -1.7667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4042   -3.2167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0167   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9542   -1.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8917   -1.8042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2292   -1.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0542   -3.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7875   -1.8750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8417   -0.4417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0542   -1.2167    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.5792   -3.2167    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.3000   -2.5250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8792   -3.2375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  1  1  0
  3  5  1  6
  6 14  1  0
  7 10  1  0
  8  1  2  0
  9  1  2  0
 10  4  1  0
 11  6  1  0
 12  4  1  0
 13  5  2  0
 14 12  1  0
 15  5  1  0
 16 11  2  0
 17 11  1  0
 18  2  1  0
 19 21  1  0
  3 20  1  0
 21 17  2  0
 22 16  1  0
 23 19  1  0
 24 15  1  0
 25 18  1  0
 26 25  1  0
  7  6  2  0
 26 20  1  0
 22 19  2  0
M  END

Associated Targets(Human)

MONO-MAC-6 (495 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 399.90Molecular Weight (Monoisotopic): 399.1020AlogP: 2.03#Rotatable Bonds: 4
Polar Surface Area: 89.95Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.71CX Basic pKa: CX LogP: 1.40CX LogD: 1.38
Aromatic Rings: 1Heavy Atoms: 26QED Weighted: 0.60Np Likeness Score: -1.13

References

1. Chen JJ, Dewdney N, Lin X, Martin RL, Walker KA, Huang J, Chu F, Eugui E, Mirkovich A, Kim Y, Sarma K, Arzeno H, Van Wart HE..  (2003)  Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs.,  13  (22): [PMID:14592482] [10.1016/j.bmcl.2003.08.076]
2. Chen JJ, Dewdney N, Lin X, Martin RL, Walker KA, Huang J, Chu F, Eugui E, Mirkovich A, Kim Y, Sarma K, Arzeno H, Van Wart HE..  (2003)  Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs.,  13  (22): [PMID:14592482] [10.1016/j.bmcl.2003.08.076]

Source